Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Cancer Cachexia
4.2.2 Strong R&D and Product Pipeline
4.3 Market Restraints
4.3.1 Stringent Regulatory Requirements
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Therapeutics
5.1.1 Progestogens
5.1.2 Corticosteroids
5.1.3 Combination Therapy
5.1.4 Others
5.2 By Mechanism of Action
5.2.1 Appetite Stimulators
5.2.2 Weight Loss Stabilizers
5.2.3 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Aeterna Zentaris
6.1.2 Alder BioPharmaceuticals Inc.
6.1.3 Aphios Corporation
6.1.4 Bristol-Myers Squibb Company
6.1.5 Pfizer
6.1.6 GTx Inc.
6.1.7 Helsinn Group
6.1.8 Merck & Co. Inc.
6.1.9 Novartis AG
6.1.10 XBiotech Inc.


7 MARKET OPPORTUNITIES AND FUTURE TRENDS